Provided by Tiger Fintech (Singapore) Pte. Ltd.

CASI Pharmaceuticals

1.92
-0.0800-4.00%
Volume:5.41K
Turnover:10.67K
Market Cap:29.75M
PE:-0.75
High:2.08
Open:2.08
Low:1.92
Close:2.00
Loading ...

CASI Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Immune Thrombocytopenia

ACCESSWIRE
·
06 Jan

BRIEF-CASI Pharmaceuticals Announces Clinical Hold Of CID-103

Reuters
·
26 Dec 2024

BUZZ-Casi Pharmaceuticals falls after FDA puts experimental antibody drug on hold

Reuters
·
26 Dec 2024

CASI Pharmaceuticals Faces Clinical Hold on CID-103 by FDA

TIPRANKS
·
26 Dec 2024

CASI Pharmaceuticals: FDA Plans to Provide Formal Written Response Before Statutory Deadline

THOMSON REUTERS
·
26 Dec 2024

CASI Pharmaceuticals Inc: Announces Clinical Hold of Cid-103 for Antibody Mediated Rejection (Amr) of Kidney Transplant

THOMSON REUTERS
·
26 Dec 2024

CASI Pharmaceuticals: Cid-103 Ind Application Supporting Phase 1-2 Study of Cid-103 in Adults With Chronic Immune Thrombocytopenia Remains Open

THOMSON REUTERS
·
26 Dec 2024

Casi Pharmaceuticals files $200M mixed securities shelf

TIPRANKS
·
21 Dec 2024

BRIEF-Casi Pharmaceuticals Inc Files For Mixed Shelf Offering Of Up To $200 Million- SEC Filing

Reuters
·
21 Dec 2024

CASI Pharmaceuticals Faces Evomela® License Termination Dispute

TIPRANKS
·
16 Dec 2024

CASI Pharmaceuticals: on Dec 13, Got Termination Process Letter for License of Evomela From Acrotech Biopharma

THOMSON REUTERS
·
16 Dec 2024

CASI Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations

Simply Wall St.
·
17 Nov 2024

CASI Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
15 Nov 2024

CASI Pharmaceuticals’ Mixed Third-Quarter Performance in 2024

TIPRANKS
·
15 Nov 2024

CASI Pharmaceuticals Inc - Qtrly Total Revenue $7.8 Mln

THOMSON REUTERS
·
15 Nov 2024

CASI Pharmaceuticals Q3 2024 GAAP EPS $(0.55) Beats $(0.62) Estimate, Sales $7.800M Beat $4.560M Estimate

Benzinga
·
15 Nov 2024

CASI Pharmaceuticals Inc expected to post a loss of 62 cents a share - Earnings Preview

Reuters
·
12 Nov 2024